On a DART-disclosed basis, annual sales went from KRW 30.1 trillion in 2022 to KRW 29 trillion in 2023 (down 3.5% year on year), KRW 29.4 trillion in 2024 (up 1.2%) and KRW 27.3 trillion in 2025 (down 6.9%). Among 2022 to 2025, 2022 was the largest year and 2025 the smallest.
Operating profit went from KRW 1.66 trillion in 2022 to KRW 1.29 trillion in 2023 (down 22.4%), recovered to KRW 1.55 trillion in 2024 (up 20.2%) and fell to KRW 1.23 trillion in 2025 (down 20.6%).
The operating margin was 5.5% in 2022, 4.5% in 2023, 5.3% in 2024 and 4.5% in 2025, so margin movements rather than sales drove profit.
Net profit attributable to owners fell from KRW 802.7 billion in 2022 to KRW 385.9 billion in 2023 (down 51.9%) and KRW 148.2 billion in 2024 (down 61.6%), then swung to a net loss of KRW 571.5 billion in 2025. Net profit including non-controlling interests was a net loss of KRW 417 billion in 2025.
Operating cash flow stayed in the KRW 2 trillion range from 2023 to 2025, at KRW 2.44 trillion, KRW 2.26 trillion and KRW 2.48 trillion.
On a quarterly basis, operating profit bottomed at KRW 204.8 billion in Q4 2025, down 40.9% from the prior quarter, and then rose to KRW 238.1 billion in Q1 2026, KRW 257.6 billion in Q2 and KRW 309 billion in Q3, three consecutive increases.
Q3 operating profit was still down 10.8% from the same quarter of the prior year. Net profit attributable to owners swung between quarters: a KRW 820.6 billion loss in Q4 2025, a KRW 81.8 billion profit in Q1 2026, a KRW 13.5 billion loss in Q2 and a KRW 19.2 billion profit in Q3, which was down 73.7% year on year.
The four most recent quarters total a KRW 733.2 billion attributable net loss. The company attributed the Q3 bottom-line drag to foreign exchange valuation losses, while freight and raw material costs were cited as additional pressure.
Bio profit fell 92.4% to KRW 5.5 billion in Q1 2026 and then recovered to KRW 108.5 billion in Q3 for the core materials unit, showing how sharply pricing moves affect quarterly results. The drivers behind the size of the Q4 2025 loss are items to confirm in the notes to the annual report.